CN1265802C - Effective extract of Chinese silkuine bark with cardotonic function and its preparing process and uasge - Google Patents
Effective extract of Chinese silkuine bark with cardotonic function and its preparing process and uasge Download PDFInfo
- Publication number
- CN1265802C CN1265802C CN 200410019975 CN200410019975A CN1265802C CN 1265802 C CN1265802 C CN 1265802C CN 200410019975 CN200410019975 CN 200410019975 CN 200410019975 A CN200410019975 A CN 200410019975A CN 1265802 C CN1265802 C CN 1265802C
- Authority
- CN
- China
- Prior art keywords
- cortex periplocae
- macroporous resin
- bark
- cardiotonic
- effective extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000284 extract Substances 0.000 title claims abstract description 59
- 238000000034 method Methods 0.000 title claims abstract description 8
- 229920005989 resin Polymers 0.000 claims abstract description 51
- 239000011347 resin Substances 0.000 claims abstract description 51
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 48
- 230000003177 cardiotonic effect Effects 0.000 claims abstract description 39
- 238000000605 extraction Methods 0.000 claims abstract description 23
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 21
- 238000002360 preparation method Methods 0.000 claims abstract description 18
- 239000002904 solvent Substances 0.000 claims abstract description 18
- 239000003480 eluent Substances 0.000 claims abstract description 9
- 239000007864 aqueous solution Substances 0.000 claims description 23
- 238000001179 sorption measurement Methods 0.000 claims description 17
- 239000012567 medical material Substances 0.000 claims description 11
- 230000001476 alcoholic effect Effects 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 10
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 4
- MPMBRWOOISTHJV-UHFFFAOYSA-N but-1-enylbenzene Chemical compound CCC=CC1=CC=CC=C1 MPMBRWOOISTHJV-UHFFFAOYSA-N 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 10
- 230000010412 perfusion Effects 0.000 abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 8
- 230000002861 ventricular Effects 0.000 abstract description 7
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract description 4
- 206010019280 Heart failures Diseases 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 4
- 230000004217 heart function Effects 0.000 abstract description 4
- 230000035488 systolic blood pressure Effects 0.000 abstract description 4
- 238000007914 intraventricular administration Methods 0.000 abstract description 3
- 230000001154 acute effect Effects 0.000 abstract description 2
- 230000001684 chronic effect Effects 0.000 abstract description 2
- 238000002474 experimental method Methods 0.000 abstract description 2
- 238000000926 separation method Methods 0.000 abstract description 2
- 235000002470 Asclepias syriaca Nutrition 0.000 abstract 8
- 241000893851 Periploca graeca Species 0.000 abstract 8
- 230000006870 function Effects 0.000 abstract 3
- 239000000463 material Substances 0.000 abstract 2
- 230000000274 adsorptive effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 15
- 241000700159 Rattus Species 0.000 description 11
- 239000000203 mixture Substances 0.000 description 9
- 239000007788 liquid Substances 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 238000010828 elution Methods 0.000 description 7
- 239000008187 granular material Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 239000002917 insecticide Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 108010011485 Aspartame Proteins 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 4
- 239000000605 aspartame Substances 0.000 description 4
- 229960003438 aspartame Drugs 0.000 description 4
- 235000010357 aspartame Nutrition 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000009194 climbing Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 238000001291 vacuum drying Methods 0.000 description 3
- 206010013786 Dry skin Diseases 0.000 description 2
- 241001406327 Periploca sepium Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000005325 percolation Methods 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000007779 soft material Substances 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- 229930002534 steroid glycoside Natural products 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 241000208327 Apocynaceae Species 0.000 description 1
- 101100313763 Arabidopsis thaliana TIM22-2 gene Proteins 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229940097217 cardiac glycoside Drugs 0.000 description 1
- 239000002368 cardiac glycoside Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- -1 reflux Substances 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000009877 shengmai Substances 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 150000008143 steroidal glycosides Chemical class 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses an effective extract of Chinese silkvine bark with a cardiotonic function, a preparing process thereof and a usage thereof. The preparing process comprises: the extraction of the medicinal material Chinese silkvine bark: the medicinal material Chinese silkvine bark is extracted with alcohol with concentration of 40% to 80% or methanol with the concentration of 40% to 100% as an extraction solvent, the solvent is steamed after extraction, and the solute is thinned by water and filtered or centrifuged to obtain the settled water solution of the Chinese silkvine bark; (2) the adsorptive separation of macroporous resin: the water solution of the Chinese silkvine bark is adsorbed with the macroporous resin, the macroporous resin is eluted with alcohol with volume 2 to 10 times greater than that of a resin bed, and the eluent is collected, concentrated and dried to obtain the effect extract of Chinese silkvine bark with a cardiotonic function. Isolated heart perfusion experiments show that under the conditions of constant-pressure and constant-flow perfusion, the effect extract of Chinese silkvine bark can obviously increase the left ventricular systolic pressure of the isolated heart of a rat, can increase the maximum upstroke velocity of intraventricular pressure and can lower left-ventricular end-diastolic pressure to improve heart functions; the effect extract of Chinese silkvine bark has the cardiotonic function and can be applied to the preparation of medicines for treating acute congestive heart failure and chronic congestive heart failure.
Description
Technical field
The invention belongs to medical technical field, be specifically related to a kind of Chinese medicine effective extract of acute and chronic congestive heart failure, preparation method of effective extract for the treatment of.
Background technology
Cortex Periplocae is the dry root bark of asclepiadaceae plant P. sepium Bunge, and the traditional Chinese medical science thinks that it has the effect of wind-damp dispelling, bone and muscle strengthening, is mainly used in anemofrigid-damp arthralgia, soreness of the waist and knees, shortness of breath and palpitation, edema of lower limbs etc.Because of Cortex Periplocae has heart tonifying and diuretic effect concurrently, other Chinese medicine composition compound recipe of the normal and QI invigorating of Cortex Periplocae, warming YANG, blood stasis dispelling, diuretic in recent years, be applied to the clinical treatment of CHF, as the compound recipe SHENGMAI YIN, heart tonifying drink, stilbene add electuary, periploca sepium mixture, heart failure spirit etc.From its preparation technology, be the compound recipe that whole part is used as medicine.Cardiac glycoside composition glucoperiplocymarin does not obtain enrichment in the Cortex Periplocae; The content of glucoperiplocymarin can not be controlled effectively.
Japan scholar Seiichi Sakama (Seiichi Sakama, et al.Constituents of Chinese Crude Drug " Wujiapi " I.Studies on the Aglycones of Steroidal Glycosides of Pei-Wujiapi (1) .Chem.Pharm.Bull, 1968,16 (2): 326) in the disclosed technology, the extraction of Cortex Periplocae is to be solvent with 95% ethanol, and is lower to the extraction efficiency of glucoperiplocymarin.Have nothing to do in the report of Cortex Periplocae extraction process the report that also has nothing to do and prepare in the effective extract of Cortex Periplocae cardiotonic thereafter.
Summary of the invention
The objective of the invention is to overcome deficiency of the prior art, a kind of Cortex Periplocae cardiotonic effective extract is provided.
Another object of the present invention provides a kind of preparation method of Cortex Periplocae cardiotonic effective extract.
Technical scheme of the present invention is summarized as follows:
Cortex Periplocae cardiotonic effective extract is to be prepared from following method:
(1) extraction of Cortex Periplocae medical material: with concentration of volume percent is that 40%～80% ethanol or 40%～100% methanol serve as to extract solvent, and Cortex Periplocae is extracted, and boils off solvent after the extraction, thin up after-filtration or centrifugal, clarifying Cortex Periplocae aqueous solution;
(2) macroporous resin adsorption is separated: the Cortex Periplocae aqueous solution is through macroporous resin adsorption, and with 2～10 times of resin bed volume of ethanol eluting, described alcoholic acid concentration of volume percent is 50%～95%, collect eluent, concentrate, after the drying, promptly get Cortex Periplocae cardiotonic effective extract.
A kind of preparation method of Cortex Periplocae cardiotonic effective extract comprises the steps:
(1) extraction of Cortex Periplocae medical material: with concentration of volume percent is that 40%～80% ethanol or 40%～100% methanol serve as to extract solvent, and Cortex Periplocae is extracted, and boils off solvent after the extraction, thin up after-filtration or centrifugal, clarifying Cortex Periplocae aqueous solution;
(2) macroporous resin adsorption is separated: the Cortex Periplocae aqueous solution is through macroporous resin adsorption, and with 2～10 times of resin bed volume of ethanol eluting, described alcoholic acid concentration of volume percent is 50%～95%, collect eluent, concentrate, after the drying, promptly get Cortex Periplocae cardiotonic effective extract.
In the leaching process of Cortex Periplocae medical material, extract the concentration of volume percent of etoh solvent and be advisable, preferably 60% with 50%～70%.
In the macroporous resin adsorption separation process, the alcoholic acid concentration of volume percent of eluting solvent is advisable with 60%～70%.
Described macroporous resin is non-polar macroporous resin or low pole macroporous resin.
Described non-polar macroporous resin is to be the macroporous resin of skeleton with styrene or ethyl styrene or α-Jia Jibenyixi.
Described low pole macroporous resin is to be the macroporous resin of skeleton with styrene.
The Cortex Periplocae aqueous solution is after macroporous resin adsorption in the described step (2), and preferably first concentration of volume percent with 1～4 times of resin bed volume is 10%～30% ethanol prewashing, reuse 60%～70% ethanol elution.
A kind of Cortex Periplocae cardiotonic effective extract of the present invention can compositions the mode of form by oral administration be applied to the patient who needs this treatment.Be used for when oral, can be made into conventional solid preparation such as tablet, granule or capsule etc.
Various dosage form of the present invention can be by the conventional production method preparation of pharmaceutical field.A kind of Cortex Periplocae cardiotonic effective extract is mixed with one or more carriers, be made into required dosage form then.
The isolated heart perfusion experiment proves: under constant voltage, the constant current perfusion condition, can significantly the raise left ventricular systolic pressure of isolated rat heart of Cortex Periplocae effective extract, increase the maximum climbing speed of intraventricular pressure, improve cardiac function, have cardiotonic thereby reduce left ventricular end-diastolic pressure; And the prewashing position does not have this effect.
Use a kind of Cortex Periplocae cardiotonic effective extract of method preparation of the present invention, removed the crude drug Cortex Periplocae with irrelevant saccharide, aminoacid, polypeptide, inorganic salt and other impurity of cardiotonic, enrichment heart tonifying composition glucoperiplocymarin, especially after 10%～30% ethanol prewashing, concentration effect is better; And greatly reduce paste-forming rate.The present invention improves dosage form for the dosage that reduces medicine, improves curative effect, and it is significant to be convenient to quality control.The present invention extracts fully glucoperiplocymarin with 40%～80% ethanol extraction; Can once finish the enrichment of remove impurity and effective ingredient with macroporous resin.This method cost is low, and is simple to operate, with practical value.
Description of drawings
Fig. 1 is the chromatogram of Cortex Periplocae effective extract;
Fig. 2 is the chromatogram at macroporous resin prewashing position;
Fig. 3 is that the Cortex Periplocae effective extract influences the isolated rat heart left ventricular systolic pressure;
Fig. 4 is that the Cortex Periplocae effective extract influences the isolated rat heart left ventricular diastolic pressure;
Fig. 5 is that the Cortex Periplocae effective extract is to the indoor maximum climbing speed influence of isolated rat heart;
Fig. 6 is that the Cortex Periplocae effective extract is to the indoor maximum fall off rate influence of isolated rat heart.
The specific embodiment
Below in conjunction with embodiment, the present invention is further illustrated:
(1) extraction of Cortex Periplocae medical material: it is 80% alcoholic solution that the 500g Cortex Periplocae adds the 3000mL concentration of volume percent, reflux, extract, 3 times, each 2 hours, merge extractive liquid,, be evaporated to about 400mL, add 600mL water dilution after-filtration, get clarifying Cortex Periplocae aqueous solution;
(2) macroporous resin adsorption is separated: with the Cortex Periplocae aqueous solution good 800mL D of pretreatment
101After macroporous resin (production of the Tianjin insecticide factory) absorption, wash with 800mL earlier, the back ethanol prewashing of 800mL 30%, reuse 1600mL 95% ethanol elution, with the eluent evaporated under reduced pressure, vacuum drying gets Cortex Periplocae cardiotonic effective extract 17.5 grams, paste-forming rate is 3.5%, and the shared mass percent of its glucoperiplocymarin is 3.18%.(if the Cortex Periplocae aqueous solution that extracts is without macroporous resin treatment, and its paste-forming rate is 21.3%, and the shared mass percent of glucoperiplocymarin is 0.52%).
The chromatogram of Cortex Periplocae effective extract is seen Fig. 1, and 1 is the glucoperiplocymarin peak among the figure; The chromatogram at prewashing position is seen Fig. 2, no glucoperiplocymarin peak among the figure.
The Cortex Periplocae effective extract is to the influence of isolated heart cardiac function
Choose 24 of healthy rats, be divided into 3 groups at random: be respectively blank group, Cortex Periplocae effective extract A group, Cortex Periplocae prewashing position B group, every group 8, the rat sacrificed by decapitation is taken out heart rapidly, place 4 ℃ of K-H liquid, discharge remained blood gently, heart is connected to Langendorff system perfusion device and fixes the beginning perfusion with silk thread, perfusate is kept 37 ℃, and feeds 95% oxygen.Connect electrocardioelectrode, after treating that electrocardio steadily, perfusion pressure is adjusted in about 46 ± 3mmHg, perfusion flow is adjusted in 6.00 ± 0.06ml/min and carries out the constant pressure and flow perfusion, left ventricular systolic pressure (LVSP), left ventricular end-diastolic pressure (LVEDP), maximum the climbing speed (± dp/dt of intraventricular pressure before the record administration of stable back
Max), heart rate (HR), slowly inject with Krebs-Henseleit liquid dissolved medicinal liquid through dosing holes, A, B group is pressed the disposable administration of 40mg crude drug/heart respectively; Blank group is given the Krebs-Henseleit liquid/heart with volume, above-mentioned every index in 10 minutes before the record administration and after the administration.
Krebs-Henseleit liquid, it consists of (mmol/L): NaCl 118,, KCl 4.7, MgSO
47H
2O 1.2,, CaCl
22.0,, NaHCO
320, KH
2PO
41.2,, glucose 11.1, pH value 7.2-7.4.
Result data sees Table 1 and table 2, accompanying drawing 3, accompanying drawing 4, accompanying drawing 5 and accompanying drawing 6.
The result shows: under constant voltage, constant current perfusion condition, and can significantly the raise LVSP of isolated rat heart of Cortex Periplocae effective extract A, increase ± dp/dt
MaxThereby, reduce LVEDP and improve cardiac function, have cardiotonic: Cortex Periplocae prewashing position B does not have this effect; A, B all do not make significant difference to the rat heart rate.
(1) extraction of Cortex Periplocae medical material: it is 40% alcoholic solution that the 500g Cortex Periplocae adds the 4000mL concentration of volume percent, carries out percolation and extracts, and extracting solution is evaporated to about 500mL, adds 500mL water dilution after-filtration, gets clarifying Cortex Periplocae aqueous solution;
(2) macroporous resin adsorption is separated: the Cortex Periplocae aqueous solution is adsorbed with the good 800mL AB-8 macroporous resin (Chemical Plant of Nankai Univ.'s production) of pretreatment, with 8000mL 50% ethanol elution, with eluent evaporated under reduced pressure solvent, get effective extract 31.0 grams of Cortex Periplocae cardiotonic, paste-forming rate 6.2%, the shared mass percent of its glucoperiplocymarin is 1.65%.
(1) extraction of Cortex Periplocae medical material: it is 70% alcoholic solution that the 500g Cortex Periplocae adds the 4000mL concentration of volume percent, and reflux, extract, 2.5 hours is extracted 2 times, merge extractive liquid,, be evaporated to about 300mL, add 700mL water dilution after-filtration, get clarifying Cortex Periplocae aqueous solution;
(2) macroporous resin adsorption is separated: with the Cortex Periplocae aqueous solution good 800mL D of pretreatment
301Macroporous resin (production of Tianjin insecticide factory) absorption with 3200mL 70% ethanol elution, evaporated under reduced pressure solvent, gets effective extract 33.6 grams of Cortex Periplocae cardiotonic, and paste-forming rate is 6.7%, and the shared mass percent of its glucoperiplocymarin is 1.57%.
(1) extraction of Cortex Periplocae medical material: it is 50% alcoholic solution merceration that the 500g Cortex Periplocae adds the 4000mL concentration of volume percent, and extracting solution is evaporated to about 300mL, adds 700mL water dilution after-filtration, gets clarifying Cortex Periplocae aqueous solution;
(2) macroporous resin adsorption is separated: the Cortex Periplocae aqueous solution is adsorbed with the good HPD100 macroporous resin of pretreatment (Cangzhou precious grace chemical industry company limited is produced), with 3200mL 70% ethanol elution, the evaporated under reduced pressure solvent, get effective extract 31.6 grams of Cortex Periplocae cardiotonic, paste-forming rate is 6.3%, and the shared mass percent of its glucoperiplocymarin is 1.73%.
(1) extraction of Cortex Periplocae medical material: it is that 40% methanol solution carries out the percolation extraction that the 500g Cortex Periplocae adds the 8000mL concentration of volume percent, and extracting solution is evaporated to about 400mL, adds 700mL water dilution after-filtration, gets clarifying Cortex Periplocae aqueous solution;
(2) macroporous resin adsorption is separated: after the Cortex Periplocae aqueous solution is tried 102 (productions of Shanghai chemical reagent work) absorption with good the going up of pretreatment, wash with 800mL earlier, the back ethanol prewashing of 3200mL 10%, reuse 8000mL 50% ethanol elution, with the eluent evaporated under reduced pressure, vacuum drying gets Cortex Periplocae cardiotonic effective extract 17.4 grams, paste-forming rate is 3.5%, and the shared mass percent of its glucoperiplocymarin is 3.72%.
(1) extraction of Cortex Periplocae medical material: the 500g Cortex Periplocae adds the 3000mL methanol solution, reflux, extract, 3 times, each 2 hours, merge extractive liquid, was evaporated to driedly, adds 800mL water dilution after-filtration, clarifying Cortex Periplocae aqueous solution;
(2) macroporous resin adsorption is separated: with the Cortex Periplocae aqueous solution good D of pretreatment
201After macroporous resin (production of Tianjin insecticide factory) adsorbs, earlier with the 1600mL washing, the back ethanol prewashing of 1600mL 30%, reuse 8000mL 60% ethanol elution, with the eluent evaporated under reduced pressure, vacuum drying gets Cortex Periplocae cardiotonic effective extract 15.8 grams.Paste-forming rate is 3.2%, and the shared mass percent of its glucoperiplocymarin is 3.87%.
When practical operation, the non-polar macroporous resin model that can also select for use is: D
101(Tianjin insecticide factory); HPD 100, or HPD 300 (Cangzhou precious grace chemical industry company limited); GDX-104 (production of Tianjin reagent two factories); SIP-1100, or SIP-1200, or SIP-1300, or SIP-1400 (Shanghai Institute of Pharmaceutical Industry); Last examination 101, or go up examination 102, or go up examination 401, or go up examination 402 (Shanghai chemical reagent works); Nanjing University 3520, or D1, or D, or Dm2, Dm5 (Chemical Plant of Nankai Univ.) or the like.The model of eligible low pole macroporous resin is: D
201Or D
101(Tianjin insecticide factory); AB-8 (Chemical Plant of Nankai Univ.); HPD 500, HPD 400 (Cangzhou precious grace chemical industry company limited); D201, D301 (Tianjin insecticide factory) or the like.In addition, can also select for use external Diaion (HP10, HP20, HP21), Amberlite (XAD-1, XAD-2).
Make tablet (1000 slice prescription):
Cortex Periplocae cardiotonic effective extract 125g
Lactose 250g
Microcrystalline Cellulose 105g
Sodium Hydroxymethyl Stalcs 15g
5%PVPK
30Solution 100ml
Aspartame 5g
Magnesium stearate 2g
Preparation method: remove PVPK
30Outside the solution, it is standby that above supplementary material is all crossed 100 mesh sieves.With Cortex Periplocae cardiotonic effective extract, lactose, microcrystalline Cellulose, Sodium Hydroxymethyl Stalcs and aspartame mix homogeneously.Use PVPK
30Solution system soft material, 16 mesh sieves are granulated, 60 ℃ of dryings and granulate.Granule behind the granulate adds magnesium stearate, mix homogeneously, tabletting.Every heavily about 0.5 gram of sheet.It is the 0.125g/ sheet that perfume (or spice) adds sheet cardiotonic effective extract content.
Usage and consumption: oral, twice, one time on the one a slice.
Make capsule (1000 prescriptions):
Cortex Periplocae cardiotonic effective extract 64g
Lactose 170g
Microcrystalline Cellulose 100g
Sodium Hydroxymethyl Stalcs 8g
5%PVPK
30Solution 80ml
Aspartame 5g
Magnesium stearate 1g
Micropowder silica gel 2g
Preparation method: remove PVPK
30Outside the solution, it is standby that above supplementary material is all crossed 100 mesh sieves.With Cortex Periplocae cardiotonic effective extract, lactose, microcrystalline Cellulose, Sodium Hydroxymethyl Stalcs and aspartame mix homogeneously.Use PVPK
30Solution system soft material, 20 mesh sieves are granulated, 60 ℃ of dryings and granulate.Granule behind the granulate adds magnesium stearate and micropowder silica gel, mix homogeneously, the capsule of packing into No. 1.Heavily about 0.35 gram of every capsules.It is the 0.064g/ grain that perfume (or spice) adds sheet cardiotonic effective extract content.
Usage and consumption: oral, one day twice, once two.
Table 1 Cortex Periplocae effective extract is to isolated rat heart LVSP (mmHg), LVEDP (mmHg) ,+dp/dtmax (mmHgs
-1) ,-dp/dtmax (mmHgs
-1) influence (x ± s)
| Group | Before the administration | After the administration | ||||||
| 1min | 2min | 3min | 4min | 5min | 10min | |||
| Blank group n=8 | LVSP LVEDP +dp/dt max -dp/dt max | 73.88±8.93 - 0.84±4.65 1018.40±195.94 - -68.55±134.19 - | 75.10±9.56 (101.61±2.76) 1.62±4.90 1040.69±187.32 (102.36±4.09) -628.86±134.93 (103.50±4.01) | 74.67±7.78 (101.37±5.08) 1.13±5.09 1032.66±168.11 (101.95±6.92) -626.94±150.02 (102.92±8.98) | 74.21±7.52 (100.83±6.05) 1.65±5.52 1014.76±161.99 (100.33±8.88) -619.66±146.60 (101.81±9.55) | 74.98±7.12 (102.02±7.45) 2.10±6.00 1020.49±145.89 (101.30±10.22) -626.87±144.70 (103.32±10.86) | 74.18±7.38 (100.89±7.30) 2.47±6.38 1009.99±149.99 (100.23±11.01) -623.57±147.37 (102.65±11.26) | 75.07±12.29 (101.45±9.13) 1.38±6.14 1032.44±221.01 (101.06±9.02) -636.32±183.83 (103.16±14.91) |
| A group n=8 1.36mg medicine/heart | LVSP LVEDP +dp/dt max -dp/dt max | 72.30±11.78 - 2.54±4.91 967.86±195.29 - -569.98±140.74 - | 88.24±16.89 * (121.66±8.50) *** 1.74±9.67 1167.00±253.79 (120.59±8.66) *** -692.21±201.75 (121.41±12.99) *** | 87.03±22.78 (119.18±13.68) ** 1.27±9.39 1145.44±249.72 (118.79±13.22) ** -692.08±208.24 (121.37±16.76) ** | 81.10±13.60 (112.37±6.91) ** 2.67±9.51 1063.92±151.76 (112.02±15.37) * -636.95±124.37 (113.81±14.02) * | 78.05±9.11 (108.85±8.34) 3.34±8.88 1019.40±122.25 (107.92±17.13) -605.00±82.17 (109.51±17.79) | 78.76±12.27 (109.92±13.44) 4.22±8.25 1004.82±129.79 (106.72±19.79) -583.12±71.20 (106.74±23.18) | 78.51±12.20 (110.14±17.58) 4.27±8.79 1075.95±304.15 (118.48±56.90) -665.52±193.19 (124.23±54.89) |
| B group n=8 0.78mg medicine/heart | LVSP LVEDP +dp/dt max -dp/dt max | 71.32±8.58 - 2.72±2.74 977.66±124.72 - -619.32±95.84 - | 74.18±10.00 # (104.03±7.24) ### 2.08±2.51 1026.45±130.98 (105.19±7.55) ### -646.07±105.29 (104.48±8.41) ### | 73.81±10.62 (103.37±7.26) ## 2.11±2.57 1022.88±136.03 (104.74±7.32) ## -649.83±94.98 (105.28±7.65) # | 72.94±10.76 (102.04±6.14) ## 2.45±3.10 1011.04±141.58 (103.39±6.59) -643.53±98.29 (104.13±7.26) | 72.77±10.83 (101.75±5.24) 2.89±3.56 1002.37±137.69 (102.50±5.90) -643.10±95.63 (104.06±6.44) | 73.81±12.72 (102.95±6.58) 3.42±4.59 1012.24±155.79 (103.30±5.86) -647.70±101.28 (104.72±6.93) | 75.03±12.92 (104.93±11.41) 3.34±3.94 1017.73±138.23 (104.33±10.23) -656.69±77.10 (107.06±12.90) |
| The F value | LVSP LVEDP +dp/dt max -dp/dt max | 0.144 - 0.485 0.187 - 0.344 - | 0.137 (21.689) 0.011 1.231 (15.497) 0.368 (9.518) | 3.113 (8.598) 0.056 1.020 (7.079) 0.350 (5.765) | 1.897 (7.911) 0.053 0.302 (2.462) 0.078 (2.852) | 1.294 (2.543) 0.074 0.045 (0.690) 0.238 (0.576) | 0.672 (1.938) 0.142 0.005 (0.462) 0.690 (0.141) | 0.498 (0.878) 0.400 0.137 (0.600) 0.070 (0.886) |
Annotate: 1. with the blank group than * P＜0.05, * * P＜0.01, * * * P＜0.001: with the A group than #P＜0.05, ##P＜0.01, ###P＜0.001
2. numerical value is numerical value before each time numerical value/administration in the bracket
*100 each numerical value rising relative value who obtains.
Table 2 Cortex Periplocae Radicis extract is to isolated rat heart heart rate (HR/timesmin
-1) influence (n=8) (x ± s)
| Group | Before the administration | After the administration | |||||
| 1min | 2min | 3min | 4min | 5min | 10min | ||
| Blank group A group B group F value | 165.18±50.83 175.07±36.01 174.71±44.47 0.144 | 155.71±48.30 169.14±18.10 164.25±40.90 0.256 | 155.52±44.06 158.42±20.85 170.94±40.84 0.399 | 154.56±40.60 161.96±16.23 167.62±35.15 0.327 | 150.89±41.29 167.86±14.16 155.03±43.16 0.498 | 159.29±44.26 165.26±17.79 153.80±43.58 0.190 | 156.44±36.76 165.30±17.06 158.90±44.11 0.143 |
Claims (8)
1. Cortex Periplocae cardiotonic effective extract is characterized in that being prepared from following method:
(1) extraction of Cortex Periplocae medical material: with concentration of volume percent is that 40%～80% ethanol or 40%～100% methanol serve as to extract solvent, and Cortex Periplocae is extracted, and boils off solvent after the extraction, thin up after-filtration or centrifugal, clarifying Cortex Periplocae aqueous solution;
(2) macroporous resin adsorption is separated: the Cortex Periplocae aqueous solution is through macroporous resin adsorption, and with 2～10 times of resin bed volume of ethanol eluting, described alcoholic acid concentration of volume percent is 50%～95%, collect eluent, concentrate, after the drying, promptly get Cortex Periplocae cardiotonic effective extract.
2. the preparation method of a Cortex Periplocae cardiotonic effective extract is characterized in that comprising the steps:
(1) extraction of Cortex Periplocae medical material: with concentration of volume percent is that 40%～80% ethanol or 40%～100% methanol serve as to extract solvent, and Cortex Periplocae is extracted, and boils off solvent after the extraction, thin up after-filtration or centrifugal, clarifying Cortex Periplocae aqueous solution;
(2) macroporous resin adsorption is separated: the Cortex Periplocae aqueous solution is through macroporous resin adsorption, and with 2～10 times of resin bed volume of ethanol eluting, described alcoholic acid concentration of volume percent is 50%～95%, collect eluent, concentrate, after the drying, promptly get Cortex Periplocae cardiotonic effective extract.
3. the preparation method of a kind of Cortex Periplocae cardiotonic effective extract according to claim 2, the concentration that it is characterized in that described extraction etoh solvent is 50%～70%.
4. the preparation method of a kind of Cortex Periplocae cardiotonic effective extract according to claim 2 is characterized in that described eluting solvent concentration of ethanol is 60%～70%.
5. the preparation method of a kind of Cortex Periplocae cardiotonic effective extract according to claim 2 is characterized in that described macroporous resin is non-polar macroporous resin or low pole macroporous resin.
6. the preparation method of a kind of Cortex Periplocae cardiotonic effective extract according to claim 5 is characterized in that described non-polar macroporous resin is is the macroporous resin of skeleton with styrene or ethyl styrene or α-Jia Jibenyixi.
7. the preparation method of a kind of Cortex Periplocae cardiotonic effective extract according to claim 5 is characterized in that described low pole macroporous resin is is the macroporous resin of skeleton with styrene.
8. the preparation method of a kind of Cortex Periplocae cardiotonic effective extract according to claim 2, it is characterized in that the Cortex Periplocae aqueous solution is after macroporous resin adsorption in the described step (2), with the prewashing of 1～4 times of resin bed volume of ethanol, described alcoholic acid concentration of volume percent is 10%～30%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410019975 CN1265802C (en) | 2004-07-13 | 2004-07-13 | Effective extract of Chinese silkuine bark with cardotonic function and its preparing process and uasge |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410019975 CN1265802C (en) | 2004-07-13 | 2004-07-13 | Effective extract of Chinese silkuine bark with cardotonic function and its preparing process and uasge |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1593503A CN1593503A (en) | 2005-03-16 |
| CN1265802C true CN1265802C (en) | 2006-07-26 |
Family
ID=34663132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410019975 Expired - Lifetime CN1265802C (en) | 2004-07-13 | 2004-07-13 | Effective extract of Chinese silkuine bark with cardotonic function and its preparing process and uasge |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1265802C (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102532229B (en) * | 2010-12-15 | 2015-01-07 | 中国科学院上海药物研究所 | Pregnane glycoside compounds with orthoester groups and applications thereof |
| CN103130903A (en) * | 2011-11-23 | 2013-06-05 | 杨凌农科大农药研究所 | Periplocoside P-farm-oriented insecticidal active compound having activating effect on insect trypsin |
| CN105987978B (en) * | 2015-02-09 | 2019-03-05 | 石家庄以岭药业股份有限公司 | Method that is a kind of while measuring 7 kinds of compounds contents in cortex periplocae |
| CN110292589A (en) * | 2018-03-22 | 2019-10-01 | 石家庄以岭药业股份有限公司 | Application of the Cortex Periplocae Radicis extract in treatment heart failure complication |
-
2004
- 2004-07-13 CN CN 200410019975 patent/CN1265802C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1593503A (en) | 2005-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1754541A (en) | Steroid saponin pharmaceutical composition and its preparation method and uses | |
| CN112870236B (en) | Flavone effective part of abelmoschus manihot and preparation method and application thereof | |
| CN1197567C (en) | Application of kaempferol and its derivative in preparing medicine for cardiac and cerebral vascular diseases | |
| CN1265802C (en) | Effective extract of Chinese silkuine bark with cardotonic function and its preparing process and uasge | |
| CN104926825A (en) | Neolignan alkane derivatives promoting neurotrophic activity, and preparation method and application thereof | |
| CN1733054A (en) | Dogwood fruit extract and its preparation process | |
| CN1947736A (en) | Prepn. method and application of injection contg. Erigeron breviscapus | |
| CN103372034A (en) | Preparation method of ginkgo biloba extract | |
| CN1850851A (en) | Method for preparing total saponins from theroots of platycodon grandiflorum utilizing weak polarity macroreticular resin and its use | |
| CN1817360A (en) | Medicinal composition for treating acute and chronic congestive heart failure, its preparation and use | |
| CN1285344C (en) | Method for preparing acanthopanax injectio | |
| CN1698717A (en) | Chinese medicinal compound fat emulsion injection and its preparation method | |
| CN1565467A (en) | Use of cornel and its extract in preparation alpha-glucosidase inhibitor medicine | |
| CN1165545C (en) | Method for separating and extracting total flavone from goldenrain tree plant and its application | |
| CN1261143C (en) | Separating preparation process of effective part and active component of influenza virus resisting medicine | |
| CN1560061A (en) | Process for extracting dioscored soap oside from dioscorea | |
| CN1853688A (en) | Chinese medicinal preparation for treating heart cerebrovascular disease and ischemic apoplexia and making method thereof | |
| CN1830458A (en) | New use of tribulus terrestris extraction | |
| CN1634325A (en) | Apocynum extract and extracting method thereof | |
| CN1068790C (en) | Medicinal composition containing total saponin extracted from stem and leaves of American ginseng | |
| CN1264506C (en) | Pharmaceutical combination containing red sage root element and preparation method thereof | |
| CN104523851A (en) | Method for extracting polygonum orientale pericarp general flavone extract product | |
| CN1234399C (en) | Method for preparing mailuoning freeze-dried powder for injection | |
| CN1634461A (en) | Honey suckle and baikal skullcap root freeze dried injection and its preparing method | |
| CN1316985C (en) | Novel use of extractive from sapan wood |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: TIANJIN TASLY PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE Effective date: 20070914 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C56 | Change in the name or address of the patentee |
Owner name: TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE Free format text: FORMER NAME OR ADDRESS: TIANJIN COLLEGE OF TRADITIONAL CHINESE MEDICINE |
|
| CP03 | Change of name, title or address |
Address after: 300193 No. 88, Nankai District, Tianjin, Yuquanlu Road Patentee after: TIANJIN University OF TRADITIONAL CHINESE MEDICINE Address before: 300193 No. 88, Nankai District, Tianjin, Yuquanlu Road Patentee before: Tianjin College of Traditional Chinese Medicine |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20070914 Address after: 300402 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Patentee after: TIANJIN TASLY PHARMACEUTICAL Co.,Ltd. Address before: 300193 No. 88, Nankai District, Tianjin, Yuquanlu Road Patentee before: TIANJIN University OF TRADITIONAL CHINESE MEDICINE |
|
| C56 | Change in the name or address of the patentee |
Owner name: TASLY PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: TIANJIN TASLY PHARMACEUTICAL CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 300402 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Patentee after: TASLY PHARMACEUTICAL GROUP Co.,Ltd. Address before: 300402 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Patentee before: TIANJIN TASLY PHARMACEUTICAL Co.,Ltd. |
|
| CP03 | Change of name, title or address |
Address after: 300410 Tianjin city Beichen District Huaihe road and road intersection Dingjiang tianzhijiao Park forensic Center for Intellectual Property Department Patentee after: TASLY PHARMACEUTICAL GROUP Co.,Ltd. Address before: 300402 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Patentee before: TASLY PHARMACEUTICAL GROUP Co.,Ltd. |
|
| CP03 | Change of name, title or address | ||
| CX01 | Expiry of patent term |
Granted publication date: 20060726 |
|
| CX01 | Expiry of patent term |